Common drug ivermectin tested in new fight against aggressive breast cancer
NCT ID NCT05318469
Summary
This early-stage study is testing whether adding the drug ivermectin to standard immunotherapy helps shrink tumors in people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination is more effective than immunotherapy alone. Researchers will measure tumor shrinkage, how long the cancer stays controlled, and patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.